News
PEPG
2.390
-3.24%
-0.080
Weekly Report: what happened at PEPG last week (1102-1106)?
Weekly Report · 17h ago
Weekly Report: what happened at PEPG last week (1026-1030)?
Weekly Report · 11/02 10:22
PepGen: Maintaining 'Hold,' PGN-EDODM1 Data Is A Major Inflection Point
Seeking Alpha · 10/31 08:20
Russell 2000 estimated to add 107 stocks in December rebalance - Stephens
Seeking Alpha · 10/29 19:12
Weekly Report: what happened at PEPG last week (1019-1023)?
Weekly Report · 10/26 10:21
Weekly Report: what happened at PEPG last week (1012-1016)?
Weekly Report · 10/19 10:21
Weekly Report: what happened at PEPG last week (1005-1009)?
Weekly Report · 10/12 10:27
PepGen Inc. (PEPG) Receives a Buy from Stifel Nicolaus
TipRanks · 10/08 13:05
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and PepGen Inc. (PEPG)
TipRanks · 10/08 10:00
Weekly Report: what happened at PEPG last week (0928-1002)?
Weekly Report · 10/05 10:26
Weekly Report: what happened at PEPG last week (0921-0925)?
Weekly Report · 09/28 10:21
Weekly Report: what happened at PEPG last week (0914-0918)?
Weekly Report · 09/21 10:21
Leerink Partners Remains a Buy on PepGen Inc. (PEPG)
TipRanks · 09/18 13:05
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 09/17 21:06
Weekly Report: what happened at PEPG last week (0907-0911)?
Weekly Report · 09/14 10:27
PepGen: Buy Rating Reiterated on Differentiated PGN-EDODM1 Program and Limited HARBOR Impact; $20 Price Target Unchanged
TipRanks · 09/09 10:46
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 09/08 21:06
Weekly Report: what happened at PEPG last week (0831-0904)?
Weekly Report · 09/07 10:20
Weekly Report: what happened at PEPG last week (0824-0828)?
Weekly Report · 08/31 10:28
Weekly Report: what happened at PEPG last week (0817-0821)?
Weekly Report · 08/24 10:28
More
Webull provides a variety of real-time PEPG stock news. You can receive the latest news about PepGen Inc through multiple platforms. This information may help you make smarter investment decisions.
About PEPG
PepGen Inc. is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies. The Company’s Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. It is focused on addressing the underlying cause of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), which have high unmet need. Its pipeline consists of two clinical stage programs, PGN-EDO51 for DMD patients who are amenable to an exon 51-skipping approach and PGN-EDODM1 for DM1 patients, and several additional preclinical stage programs. Its product candidates also include PGN-EDO53, PGN-EDO45 and PGN-EDO44.